MedTrace Logo

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2021-12-08

No results posted yet for this study

Summary

randomized, double-blind, placebo controlled

Conditions

  • Bioequivalence

Interventions

DRUG

Oxymetazoline hydrochloride Cream, 1%

Cream

DRUG

Rhofade™ (oxymetazoline) cream, 1%

cream

DRUG

Placebo

cream

Sponsors & Collaborators

  • Sun Pharmaceutical Industries, Inc.

    lead INDUSTRY

Principal Investigators

  • Kelly Walker · WayCro / Trial Clinsultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-23
Primary Completion
2019-03-21
Completion
2019-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05148689 on ClinicalTrials.gov